Background: The purpose of the NCRAS Urological Cancer Site-Specific Clinical Reference Group (SSCRG) is to link the knowledge of clinicians with the large amount of routine data collected by cancer registration. This study considers the latest available data and trends in incidence, mortality and survival and offers interpretation of findings in a clinical context. Methods: New diagnoses of urological cancer in England for 2001 to 2013 were extracted from the National Cancer Registration and Analysis Service (NCRAS). Deaths were counted from Office for National Statistics (ONS) data for the same years. Directly age-standardised rates (ASRs) and net survival were calculated. Results: Prostate cancer incidence has increased to 40,000 cases per year. Mortality rates are falling and hence the improvement seen in five-year survival is likely to be due to changes in treatment rather than artefact. Bladder cancer (including CIS and pTa disease) shows a stable incidence and decreasing mortality rates. Survival from T1-T4 bladder cancer is stable. There has been a marked rise in kidney cancer incidence in both sexes with a stable mortality. The stable mortality suggests that improved five-year survival may be an artefact due to increased detection as a result of more widespread use of diagnostic imaging. Incidence of upper-urinary-tract cancer has risen both for invasive and non-invasive disease, and mortality in men has risen for invasive disease. This may be down to better recognition and attribution of disease. Testicular cancer has shown little change. Deaths are now rare, and survival is the highest for any cancer. There have been no significant changes in penis cancer, which remains the rarest urological cancer. Conclusion: The epidemiological data suggest a generally improving picture for urological cancer. However, there are some areas which require further consideration. Population-based studies can show variation in rare cancers and highlight previously unrecognised inequalities.
Introduction
The purpose of the National Cancer Registration and Analysis Service (NCRAS) Urological Cancer Site-Specific Clinical Reference Group (SSCRG) is to link the knowledge of clinicians with the large amount of routine data collected by cancer registration. The urological cancer SSCRG covers six sites: penis, testis, prostate, bladder, kidney and urinary upper-tract. Part of its work programme is to monitor and comment upon trends in key statistics relating to cancer, namely incidence, mortality and survival. This study therefore considers the latest available data and offers interpretation of findings in a clinical context.
Method
New diagnoses of urological cancer for 2001 to 2013 were extracted from NCRAS. Cases were identified using International Statistical Classification of Diseases and Related Health Problems, 10th revision (ICD-10) codes C60 (penile), C61 (prostate), C62 (testis), C64 (kidney), C65+C66 (upper tract) and C67 (bladder). For some analyses the data include D-coded neoplasms, which are those of uncertain behaviour or are carcinoma in situ (cis). These were bladder (D090, D414), renal pelvis/ureter (D411, D412) and penis cancer (D074).
Deaths were counted from Office for National Statistics (ONS) data for the same years, where the derived underlying cause of death was one of the ICD-10 codes listed above.
Directly age-standardised rates (ASRs) were produced using the 2013 European Standard Population. Differences described in the text are statistically significant, and are defined as changes seen between 2001 and 2013 where confidence intervals do not overlap.
The survival figures are for net survival adjusted for expected mortality by age, sex, deprivation, year and region of residence. The difference between the expected and observed survival is shown in the survival curves, yielding an estimate of cause-specific mortality.
Prostate cancer
There has been a marked rise in the crude incidence since 2001, from 27,939 to 40,467 cases. However, the rise in the ASR has been much more modest ( Figure 1 ) and a recent subtle acceleration in increase may reflect changes in the more widespread use of prostate-specific antigen (PSA) testing and/or earlier diagnosis. Prostate cancer mortality continues to fall and therefore the improvement seen in five-year survival is likely to be due to changes in treatment rather than artefact. This reflects changes in radical treatment options, the greater uptake of active surveillance linked to a stage shift towards low-and intermediate-risk disease, increasing use of radical treatment in high-risk disease and advancement in systemic treatments for castrate-resistant disease.
Bladder cancer
Bladder cancer is a disease which is defined differently by epidemiologists and urologists. Bladder cancer, coded as C67, refers only to those patients with invasive disease (⩾ pT1). D090 is labelled cis but includes cis, G3pTa and latterly G2pTa. D414 relates to bladder lesion of uncertain behaviour and includes inverted papilloma, papillary urothelial neoplasm of low malignant potential (PUNLMP), G1PTa and G2pTa. G2pTa has been coded as cis since 2012.This coding change has led to a marked rise in D090 and a fall in D414 (Figure 2 ). Urologists usually regard pTa and cis as forms of bladder cancer. Hence it is difficult to describe the epidemiology of bladder cancer from a urologist's perspective without including the D codes. Figure 3 shows the data for invasive bladder cancer only (C67 i.e. ⩾ T1). The overall incidence is falling and there are small decreases in mortality in both sexes while survival remains unchanged. There remains a survival detriment for females with bladder cancer; this is discussed in detail elsewhere in this supplement. Figures 4 and 5 show data for all bladder cancers (C67 + D090 + D414).
These show a stable incidence and a falling mortality in males. This is in contrast to a recent United Kingdom (UK) report which suggests falling incidence and stable mortality. 1 Two explanations seem possible, firstly that due to increasing use of the two-week wait referral pathway 2 diagnosis is made at an earlier stage. This seems to be at odds with the fact that pTa 'bladder cancer' progresses to invasion fairly infrequently. Secondly a coding change in year 2000 moved many 'bladder cancers' without invasion out of the C67 code. This process was thought to be complete but if it were delayed it might explain these findings.
Kidney cancer
There has been a marked rise in incidence in both sexes with a stable mortality ( Figure 6 ). This is consistent with similar findings seen in other parts of the world. The stable mortality suggests that improved five-year survival may be an artefact due to increased detection as a result of more widespread use of diagnostic imaging.
Upper-urinary-tract cancer (UTTCC)
UTTCC has many similarities to bladder cancer and has a similar coding structure. pTa and cis are coded using D codes while C64 and C65 relate only to disease ⩾ T1.
There has been a marked rise in incidence both for invasive and non-invasive disease, and mortality in men has risen for invasive disease (Figure 7) .
When invasive and non-invasive diseases are combined there is no significant change in mortality or survival (Figures 8 and 9 ).
Undoubtedly some of the change in incidence is due to better recognition due to the introduction of computed tomography (CT) urography. This may also account for the increase in mortality, as cause of death can now be correctly attributed more often. There has also been a change in biopsy practice over the period under examination, and flexible ureteroscopy has become a standard diagnostic test, hence more patients now have definitive histology.
Testis cancer
No significant changes were seen in patients with testis cancer (Figure 10 ). Incidence remains low, with about 2000 diagnoses each year, and survival remains at the highest level for all cancers. Deaths from testicular cancer are now extremely uncommon; about 50 a year.
Penis cancer
There have been no significant changes in penis cancer ( Figure 11 ) although there is a trend towards a small rise in incidence and a fall in mortality. It is the rarest urological cancer with about 500 cases and 90 deaths each year. 
